Jan Panteli
Director, Upstream Process Development, Gene Therapy Ultragenyx Pharmaceutical Inc.
Jan Panteli is a Senior Director of Upstream Process Development and CMC Program Lead at Ultragenyx Pharmaceutical, a company focused on developing therapies for rare and ultra-rare genetic diseases. With a multidisciplinary background spanning bioprocess and chemical engineering, cell culture, molecular biology, and data analysis, he supports upstream development and scale-up efforts for AAV gene therapies. In his role, Jan works closely with cross-functional teams to help translate scientific advances into scalable and manufacturable processes that support clinical and commercial programs. Jan is motivated by the opportunity to contribute to the development of therapies that address significant unmet medical needs and to support progress for patients and families affected by rare diseases worldwide.
Seminars
Not every challenge in process monitoring warrants a long deep dive. This quick‑fire solutions session is designed to surface common adoption and implementation barriers – and address them head‑on with practical, experience‑led insights from across the room.
Through a series of focused prompts and rapid audience discussion, participants will share what has worked, what hasn’t, and where small changes have delivered disproportionate impact. The goal is to help teams move past minor but persistent obstacles that slow adoption, drain resources, and delay ROI.
Topics to be covered include:
- Does lean chemometrics have a place in PAT?
- Advancing Process Monitoring & Control Strategies in Gene Therapy Manufacturing
- When to take the right sample at the right time?
- Low‑cost wins that improved monitoring adoption fastest
- Getting CMOs on board without changing validated systems
